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Abstract
Introduction: Today, we frequently find patients taking oral anticoagulant therapy (OAT), a prophylaxis against the
occurrence of thromboembolic events. An oral surgeon needs to know how to better manage such patients, in
order to avoid hemorrhagic and thromboembolic complications.
Materials and methods: A group of 193 patients (119 men aged between 46 and 82 and 74 women aged
between 54 and 76) undergoing OAT for more than 5 years were managed with a standardized management
protocol and a 2-months follow-up. The aim of the present study was to apply a protocol, which could provide a
safe intra- and postoperative management of patients on OAT.
Results: Among the 193 patients, only 2 had postoperative complications.
Conclusions: We think that the protocol used in the present study can be used for complete safety in the
treatment of this type of patients.
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Introduction
The typology of coagulation disorders is extremely het-
erogeneous. Today, we frequently treat patients taking
oral anticoagulant therapy (OAT), a prophylaxis against
the occurrence of thromboembolic events [1,2].
Recent studies on the Italian population indicate an
estimated 250.000 patients taking OAT to date. Indica-
tions for use of this pharmacological prophylaxis [3,4]
are confirmed by cardiac diseases, vasculopathies with
thromboembolic etiology, a few enzymatic-receptorial
anomalies, as well as qualitative/quantitative alterations
of some cellular hematic components [5,6].
Today, we deal with patients undergoing dicoumaro-
lics therapy, which interfere with the metabolism of vita-
min K and therefore with the synthesis of coagulation
factors– I I ,V I I ,I X ,a n dX[ 7 , 8 ] .T h e s ep a t i e n t so f t e n
take the most frequent OAT, such as:
￿ acenocoumarol: intermediate action, which begins
within 24-48 h and ends within 2-4 days.
￿ warfarin: long and delayed action from 3 to 7 days.
Warfarin has a more permanent and long-lasting
effect, because of its longer biological half-life (about
36 h).
The aim of the present study was to apply a protocol,
which could provide a safe intra- and postoperative
management of patients on OAT.
Materials and methods
In the present multicentric study, we focused on a
cohort of 193 patients (119 men aged between 46 and
82 years and 74 women aged between 54 and 76 years)
undergoing OAT for more than 5 years.
This study is carried out in compliance with the Hel-
sinki Declaration; it is divided into a preoperative phase,
an intraoperative phase,a n dapostoperative phase
including a 2-months follow-up.
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Medical history was carried out through specific question-
naires for the diagnosis of hemorrhagic disorders [9]. We
asked the patients if they ever had hemorrhagic diathesis,
its type (spontaneous or post-traumatic/post-surgical), and
outcome. It is important to ask the patients if they drink
alcohol or take unnecessary substances [10]. A careful
assessment of the ongoing pharmacological therapy should
be carried out. Some currently used drugs (such as penicil-
lin and cephalosporin, trimetoprim, gentamicin, rifampi-
cin, analgesics and non-steroidal anti-inflammatory drugs
(NSAIDS), cardiovascular and anti-diabetic drugs, diure-
tics, platelet anti-aggregants, heparins, gold salts, and anti
H2) can produce thrombocytopenia [5].
￿ On the day of the surgery, the dental surgeon has to
investigate the patient’s hemocoagulative structure
through a series of hematoclinical examinations.
Counseling between the dental surgeon, patient, and
hygienist is necessary to make patients aware of the
importance of dental hygiene in preventing dental and
periodontal pathologies, which could later require more
destructive and invasive therapies [11].
In addition to this, inflammatory or degenerative
pathologies of the oral cavity play a crucial role in the
genesis of bacterial endocarditis, a non-rare phenom-
enon among chronic valvulopathy patients and among
those with valvular prostheses [12].
Bacterial Endocarditis (BE) is a potentially lethal dis-
ease, even if patients are on antibiotics. Mortality can
reach up to 30% of cases.
The British Society Antimicrobial Chemotherapy
(BSAC) has revised the cardiac table of patients risking
BE. According to these new indications, there are 3
types of patients risking BE:
1) patients with previous BE; 2) patients with cardiac
valve replacement; and 3) patients who underwent surgi-
cal shunt creation, especially in the cardiopulmonary
area.
These new guidelines are no longer ambiguous about
performing an antibiotic prophylaxis (table 1) apart
from the routinely removal of infections during the days
preceding the oral surgery.
The aim of antibiotic prophylaxis is to have an effec-
tive serum concentration of the active principle during
the whole perioperative period.
The antibiotic therapy should be given shortly after
the beginning of the treatment (1-2 h) and within 6-8 h
from surgery; a longer therapy is justified only in case of
infected tissues or delayed wound healing.
b) Intra-operative phase
Fifteen days before surgery, periodontal preparation of
patients through tartar ablation by means of an ultraso-
nic equipment. To avoid periodontal hemorrhages, it is
necessary to invite patients (before ablation) to do oral
rinses for 1 min, with 10 ml of 4.8% solution of tranexa-
mic acid. Moreover, it is important to prescribe to
patients oral rinses with chlorhexidine digluconate
0.12%, 2 times a day for 14 days before surgery.
The day of surgery, it is necessary to assess the hemo-
coagulative parameters by taking a blood sample, which
will allow to evaluate PT, PTT, and especially the INR
measured 24 h before surgery.
In the last 3 years, we treated 193 patients on OAT
with a standardized management and a 2-months fol-
low-up. Although we evaluated every single clinical case
in its uniqueness, we wanted to apply a protocol provid-
ing for a safe intra- and postoperative management of
patients receiving OAT.
There are not any contraindications to the use of local
anesthetics: mepivacaine, lidocaine, or articaine are recom-
mended (articaine is needed when an intense ischemia is
required and when surgery lasts more than 1 h, thanks to
its longer action than mepivacaine and to its good effec-
tiveness in controlling postoperative pain).
The literature does not recommend the use of vasocon-
strictors as they could cause tachycardia episodes [13];
nevertheless, we think that a safe use of a vasoconstrictor
is possible by means of an aspirating syringe (carpule)
and a good anesthesia technique, except for patients who
recently had a myocardial infarction or coronary artery
bypass surgery (≤ 8 months).
This will bring 2 advantages:
1) The vasoconstrictor will guarantee an optimal zonal
ischemia and a longer anesthetic effect, which is very
useful when treating hemorrhagic patients [14];
2) The vasoconstrictor (red phials) allows for an effective
anesthesia, using a smaller quantity of anesthetic com-
pared to green phials (anesthetic without vasoconstrictor).
Among the hemostatic agents that a dental surgeon
can use, there are ferric sulfate, oxidized cellulose, gela-
tin sponges, and anti-fibrinolytics.
Oxidized regenerated cellulose [15] (Surgicel, Tabo-
tamp) consists of a sterile gauze and oxidized cellulose.
First, it acts as a mechanical barrier and then as a vis-
cous mass, which works as an artificial clot.
Antifibrinolytics (Tranex, Ugurol)p e r f o r mag o o d
local hemostatic action.
Local use of tranexamic acid to prevent and treat
hemorrhage in the oral cavity is recommended. The use
of this active principle encourages clot formation and
reduces the bleeding time [16].
Before surgery, we perform a standardized preopera-
tive procedure.
We recommend a pre-anesthesia by administering ben-
zodiazepines (15 gtts, 20 min. before surgery). As a mat-
ter of fact, premedication allows for greater patient
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caused by intraoperative stress will be avoided.
We suggest to our patients oral rinses with chlorhexi-
dine digluconate 0.2% solution [17].
A careful disinfection of perioral and intraoral mucus-
dental tissues by using an iodized solution is also neces-
sary. Rinsing the operating field with tranexamic acid
solution (4.8%) allows to control hemostasis since initial
dieresis.
Performing a venous access allows to operate quickly in
case of hemorrhagic emergency. In this case, patients
could have hypotensive phenomena, which involve diffi-
cult identification of the venous access, because vessels
could be partially collapsed.
In major oral surgery, 2 g of tranexamic acid are
administered intravenously (IV) 1 h before surgery
(divided into 4 × 0.5 g doses every 15 min) and after
preparing the venous access [16].
The cardiac activity and the pressure status have to be
steadily monitored using specific equipment (Cardioca-
pII, Datex).
The surgical procedure is performed following a stan-
dardized controlled protocol.
A plexus, intraligamentous,o rlocoregional anesthesia is
performed using a slow infusion of mepivacaine 3%; we
have described above what we think about the use of vaso-
constrictors, which will bring more benefits than objective
risks. Following a periotome syndesmotomy, a luxation of
the dental-alveolar gomphosis will be performed. We sug-
gest to reduce to a minimum the use of surgical elevators,
because the moments of force of these instruments cause
severe trauma to soft tissues along with microlesions to
the alveolar ridge. After avulsion, manual reduction of the
“greenstick” fracture [2] of the post-extractive alveolus will
be performed by two-finger compression of the vestibular
and lingual-palatal alveolus portions, in order to reduce
the fracture occurred during avulsion.
Accurate alveolar bone cleaning is to perform: by
means of an alveolar spoon, we will remove all the pos-
sible granulation tissues representing the primum
movens in the residual cyst formation, namely post-
extractive alveolites [1,2].
Ab o n er o n g e u ro rab o n em i l lw i t hat u r b i n em o t o r
(continuous irrigation) allows to eliminate the bone
roughness, which could damage the soft tissues of the
antagonist arch. We compressed the post-extraction
alveolus with oxidized regenerated cellulose.
we suggest an absorbable suture (Vicryl 3/0 or 4/0 to
avoid trauma of suture removal) using a “simple running
stitch,” with a further safety suture using a “simple inter-
rupted stitch"; then, there will be a 30 minute compres-
sion of the surgical area, followed by sterile gauze
application filled with tranexamic acid. If bleeding stops
about 30 min later, it is the clinical demonstration of
the technical success of surgery.
c) Post-operative phase
Patients should be discharged at least 60 minutes after
surgery (in order to verify the absence of hemorrhagy);
we advise a cold and liquid diet during the next 3 days
and a tepid and semiliquid diet during the following
3 days.
Patients should perform oral rinses for 2 minutes with
10 ml of tranexamic acid, 4 times a day for 7 days [16].
Table 1 Pattern of Antibiotic Prophylaxis
DRUGS DOSAGE
FIRST CHOICE
Amoxicillin Adults: 2 gm per os, 1 hour before surgery
1,5 gm per os, 6 hours after initial dose
Children: 50 mg/Kg per os, 1 hour before surgery
PATIENTS UNABLE TO TAKE DRUGS PER OS
Ampicillin Adults: 2 gm i.m., before surgery
Children: 50 mg/Kg ev or im, 30 min before surgery
IN CASE OF ALLERGY TO PENICILLIN
Clindamycin
Cephalexin* or Cephadroxil*
Azithromycin or Clarithromycin
Adults: 600 mg per os, 1 hour before surgery
Children: 20 mg/Kg per os, 1 hour before surgery
Adults: 2 gr per os, 1 hour before surgery
Children: 50 mg/Kg per os, 1 hour before surgery
Adults: 500 mg × os 1 hour before surgery
Children: 15 mg/Kg per os, 1 hour before surgery
ALLERGIC PATIENTS UNABLE TO TAKE DRUGS PER OS
Clindamycin
Cephazolin*
Adults: 600 mg ev, 30 min before surgery
Children: 20 mg/Kg ev, 30 min before surgery
Adults: 1 gr im, 30 min before surgery
Children: 25 mg/Kg im or ev, 30 min before surgery
*provided that there are no serious allergic reactions to penicillin.
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an hour.
During the first 30 days after surgery, we suggest
patients to rinse their mouth every 12 h with chlorhexi-
dine digluconate 0.12% solution; anti-inflammatory ther-
apy should be prescribed only in case of complex surgeries
or if patients experience postoperative pain: 500 mg of
paracetamol every 8 hours will be a precaution against
hemorrhagic problems caused by the NSAIDs.
The highest risk of postoperative hemorrhagic dia-
thesis is during the first 12 h after the surgery; our fol-
low-ups allow us to exclude hemorrhagic relapse from
the 6
th day after the surgery.
In case of postoperative hemorrhage, a buffer imbibed
in tranexamic acid should be applied together with com-
pression of the area [18]; if bleeding persists, up to 2 g of
tranexamic acid divided into 4 doses of 0.5 g has to be
administered. In incoercible cases, it is indispensable to
consult the hematologist in order to reduce OAT and
develop a strategy to stop hemorrhagic diathesis [19,20].
We recommend the use of absorbable sutures (Vicryl
3/0 or 4/0) t oa v o i dt r a u m ac a u s e db ys u t u r er e m o v a l .
Non-absorbable sutures are particularly indicated for
areas presenting aponeurosis, mimic muscles, frenula,
etc. Removal should nonetheless be performed on the
8
th day and in the less traumatic way. In case of slight
hemorrhages, it is enough to apply a tampon of tranexa-
mic acid and repeat oral rinses for 1 or 2 days.
Regular follow-ups should be planned (7, 15, 30, and
60 days after surgery). They include intra- and extraoral
examinations, a measurement of symptoms of pain by
visual analogue scale (VAS), the motivation of patients
to oral hygiene, and the possibility of further dental
treatments.
Results
Out of 193 treated patients, just 2 of them (only 1.03% of
cases) had problems related to surgery: the 1
st one had a
slight hematoma in the area of labial commissure, due to
the trauma caused by the Farabeuf retractor, but it
regressed in a few days. The 2
nd one had pains and did not
present clot formation in the post-extractive site. Intraoral
examination confirmed the diagnosis of post-extractive
alveolitis, while the forthcoming pathological medical his-
tory indicated that the patient did not follow hygiene rules
(smoker) in the immediate postoperative period; the alveo-
lus was cleaned and the symptoms significantly reduced in
the follow-up period.
The results of this study show a protocol which allows
a safe treatment of patients on OAT.
The problems that may principally arise in this type of
surgical patients are related to a deficient or excessive
clotting, we may also have problems of excessive sus-
ceptibility to bacterial infections. With this protocol we
have treated 193 patients and we have had none of
these problems, except in only 2 cases. These data are
significant and show that the management of these
patients is possible if we follow a proper protocol such
as this one here described.
Discussion
Dental procedures represent a particularly common
intervention for patients receiving anticoagulant therapy.
The most recent literature indicated that in most cases,
no change in the intensity of anticoagulation is needed.
As we can highlight in the literature, there are no well-
documented cases of severe bleeding in this setting, but
there are many documented cases of embolic events in
patients whose warfarin therapy was discontinued for
dental treatment. If there is a need to control local
bleeding, tranexamic acid administration has been used
successfully without interrupting anticoagulant therapy
[18,19].
The diathesis of bleeding is significantly related to the
intensity of the anticoagulant effect. Therefore, in patients
who show a severe bleeding, every effort should be made
to maintain the INR at the lower limit of the therapeutic
range. For patients with mechanical prosthetic valves (and
a persisting risk of increased bleeding), it would be reason-
able to aim for an INR range of 2.0 to 2.5. For patients
with atrial fibrillation (and a persisting risk of increased
bleeding), the anticoagulant intensity can be reduced to an
INR range of 1.5 to 2.0 with the expectation that efficacy
will be reduced but not abolished. Alternatively, aspirin
can be used to replace warfarin in patients with atrial
fibrillation, but also with a reduced efficacy in high-risk
patients [21].
In the past, the scientific literature often recommended
OAT interruption in order to avoid intra- and postopera-
tive hemorrhagic risk: in a research carried out in 1996 in
the USA, around 70% of clinicians recommended their
patients to interrupt anticoagulant treatment before
undergoing dental treatments, with a risk of hemorrhage.
In this light, we want to underline how the interruption of
an anticoagulant therapy, even for a short time, exposes
the patient to thromboembolic risks, even many days after
treatment: the analysis of 500 documented cases of
patients who suspended an anticoagulant therapy to
undergo oral surgery revealed that 5 patients (0.95%) had
thromboembolic episodes; 4 of them had fatal throm-
boembolism, while 1 patient had 2 embolic non-fatal
episodes [3].
A randomized study showed how OAT interruption to
perform minor oral surgery does not imply any real
clinical benefit [4,5].
Even in those cases in which we are performing surgi-
cal treatments particularly invasive, or we are treating a
syndromic condition closely related to an augmented
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association between a conscious administration of tra-
nexamic acid and a well done surgical performance,
especially if we follow a well documented protocol
[22,23].
Conclusions
We think that the protocol analyzed in the present
study can be used in complete safety for the treatment
patients receiving OAT, even though a few factors can
alter the patient response to the protocol. The recom-
mendations that urge to maintain the INR at the lower
limit of the therapeutic range are still actual, although,
the evaluations to do are closely related to each patient,
to his general conditions and to the typology of oral sur-
gery to perform.
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